Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carsten G. Bönnemann is active.

Publication


Featured researches published by Carsten G. Bönnemann.


Science | 1995

Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy

S. Noguchi; Elizabeth M. McNally; Kamel Ben Othmane; Yasuko Hagiwara; Yuji Mizuno; Mikiharu Yoshida; Hideko Yamamoto; Carsten G. Bönnemann; Emanuela Gussoni; Peter H. Denton; Theodoros Kyriakides; Lefkos Middleton; F. Hentati; Mongi Ben Hamida; Ikuya Nonaka; Jeffery M. Vance; Louis M. Kunkel; Eijiro Ozawa

Severe childhood autosomal recessive muscular dystrophy (SCARMD) is a progressive muscle-wasting disorder common in North Africa that segregates with microsatellite markers at chromosome 13q12. Here, it is shown that a mutation in the gene encoding the 35-kilodalton dystrophin-associated glycoprotein, γ-sarcoglycan, is likely to be the primary genetic defect in this disorder. The human γ-sarcoglycan gene was mapped to chromosome 13q12, and deletions that alter its reading frame were identified in three families and one of four sporadic cases of SCARMD. These mutations not only affect γ-sarcoglycan but also disrupt the integrity of the entire sarcoglycan complex.


Nature Genetics | 1995

β–sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex

Carsten G. Bönnemann; Raju Modi; S. Noguchi; Yuji Mizuno; Mikiharu Yoshida; Emanuela Gussoni; Elizabeth M. McNally; David J. Duggan; Corrado Angelini; Eric P. Hoffman; Eijiro Ozawa; Louis M. Kunkel

The dystrophin associated proteins (DAPs) are good candidates for harboring primary mutations in the genetically heterogeneous autosomal recessive muscular dystrophies (ARMD). The transmembrane components of the DAPs can be separated into the dystroglycan and the sarcoglycan complexes. Here we report the isolation of cDNAs encoding the 43 kD sarcoglycan protein β–sarcoglycan (A3b) and the localization of the human gene to chromosome 4q12. We describe a young girl with ARMD with truncating mutations on both alleles. Immunostaining of her muscle biopsy shows specific loss of the components of the sarcoglycan complex β–sarcoglycan, α–sarcoglycan (adhalin), and 35 kD sarcoglycan). Thus secondary destabilization of the sarcoglycan complex may be an important pathophysiological event in ARMD.


American Journal of Human Genetics | 2013

Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of α-Dystroglycan

Keren J. Carss; Elizabeth Stevens; A. Reghan Foley; Sebahattin Cirak; Moniek Riemersma; Silvia Torelli; Alexander Hoischen; Tobias Willer; Monique van Scherpenzeel; Steven A. Moore; Sonia Messina; Enrico Bertini; Carsten G. Bönnemann; Jose E. Abdenur; Carla Grosmann; Akanchha Kesari; R. Quinlivan; Leigh B. Waddell; Helen Young; Elizabeth Wraige; Shu Yau; Lina Brodd; L. Feng; C. Sewry; Daniel G. MacArthur; Kathryn N. North; Eric P. Hoffman; Derek L. Stemple; Hans van Bokhoven; Kevin P. Campbell

Congenital muscular dystrophies with hypoglycosylation of α-dystroglycan (α-DG) are a heterogeneous group of disorders often associated with brain and eye defects in addition to muscular dystrophy. Causative variants in 14 genes thought to be involved in the glycosylation of α-DG have been identified thus far. Allelic mutations in these genes might also cause milder limb-girdle muscular dystrophy phenotypes. Using a combination of exome and Sanger sequencing in eight unrelated individuals, we present evidence that mutations in guanosine diphosphate mannose (GDP-mannose) pyrophosphorylase B (GMPPB) can result in muscular dystrophy variants with hypoglycosylated α-DG. GMPPB catalyzes the formation of GDP-mannose from GTP and mannose-1-phosphate. GDP-mannose is required for O-mannosylation of proteins, including α-DG, and it is the substrate of cytosolic mannosyltransferases. We found reduced α-DG glycosylation in the muscle biopsies of affected individuals and in available fibroblasts. Overexpression of wild-type GMPPB in fibroblasts from an affected individual partially restored glycosylation of α-DG. Whereas wild-type GMPPB localized to the cytoplasm, five of the identified missense mutations caused formation of aggregates in the cytoplasm or near membrane protrusions. Additionally, knockdown of the GMPPB ortholog in zebrafish caused structural muscle defects with decreased motility, eye abnormalities, and reduced glycosylation of α-DG. Together, these data indicate that GMPPB mutations are responsible for congenital and limb-girdle muscular dystrophies with hypoglycosylation of α-DG.


Neuromuscular Disorders | 2014

Diagnostic approach to the congenital muscular dystrophies

Carsten G. Bönnemann; Ching C.H. Wang; Susana Quijano-Roy; Nicolas Deconinck; Enrico Bertini; Ana Ferreiro; Francesco Muntoni; C. Sewry; Christophe Béroud; Katherine D. Mathews; Steven A. Moore; Jonathan Bellini; Anne Rutkowski; Kathryn N. North

Congenital muscular dystrophies (CMDs) are early onset disorders of muscle with histological features suggesting a dystrophic process. The congenital muscular dystrophies as a group encompass great clinical and genetic heterogeneity so that achieving an accurate genetic diagnosis has become increasingly challenging, even in the age of next generation sequencing. In this document we review the diagnostic features, differential diagnostic considerations and available diagnostic tools for the various CMD subtypes and provide a systematic guide to the use of these resources for achieving an accurate molecular diagnosis. An International Committee on the Standard of Care for Congenital Muscular Dystrophies composed of experts on various aspects relevant to the CMDs performed a review of the available literature as well as of the unpublished expertise represented by the members of the committee and their contacts. This process was refined by two rounds of online surveys and followed by a three-day meeting at which the conclusions were presented and further refined. The combined consensus summarized in this document allows the physician to recognize the presence of a CMD in a child with weakness based on history, clinical examination, muscle biopsy results, and imaging. It will be helpful in suspecting a specific CMD subtype in order to prioritize testing to arrive at a final genetic diagnosis.


Journal of Clinical Investigation | 2014

Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy

Michaela Yuen; Sarah A. Sandaradura; James J. Dowling; Alla S. Kostyukova; Natalia Moroz; Kate G. R. Quinlan; Vilma-Lotta Lehtokari; Gianina Ravenscroft; Emily J. Todd; Ozge Ceyhan-Birsoy; David S. Gokhin; Jérome Maluenda; Monkol Lek; Flora Nolent; Christopher T. Pappas; Stefanie M. Novak; Adele D’Amico; Edoardo Malfatti; Brett Thomas; Stacey Gabriel; Namrata Gupta; Mark J. Daly; Biljana Ilkovski; Peter J. Houweling; Ann E. Davidson; Lindsay C. Swanson; Catherine A. Brownstein; Vandana Gupta; Livija Medne; Patrick Shannon

Nemaline myopathy (NM) is a genetic muscle disorder characterized by muscle dysfunction and electron-dense protein accumulations (nemaline bodies) in myofibers. Pathogenic mutations have been described in 9 genes to date, but the genetic basis remains unknown in many cases. Here, using an approach that combined whole-exome sequencing (WES) and Sanger sequencing, we identified homozygous or compound heterozygous variants in LMOD3 in 21 patients from 14 families with severe, usually lethal, NM. LMOD3 encodes leiomodin-3 (LMOD3), a 65-kDa protein expressed in skeletal and cardiac muscle. LMOD3 was expressed from early stages of muscle differentiation; localized to actin thin filaments, with enrichment near the pointed ends; and had strong actin filament-nucleating activity. Loss of LMOD3 in patient muscle resulted in shortening and disorganization of thin filaments. Knockdown of lmod3 in zebrafish replicated NM-associated functional and pathological phenotypes. Together, these findings indicate that mutations in the gene encoding LMOD3 underlie congenital myopathy and demonstrate that LMOD3 is essential for the organization of sarcomeric thin filaments in skeletal muscle.


American Journal of Human Genetics | 2012

Mutations in FKBP14 cause a variant of Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss.

Matthias Baumann; Cecilia Giunta; Birgit Krabichler; Franz Rüschendorf; Nicoletta Zoppi; Marina Colombi; Reginald E. Bittner; Susana Quijano-Roy; Francesco Muntoni; Sebahattin Cirak; Gudrun Schreiber; Y. Zou; Ying Hu; Norma B. Romero; Robert Yves Carlier; Albert Amberger; Andrea J. Deutschmann; Volker Straub; Marianne Rohrbach; Beat Steinmann; Kevin Rostasy; Daniela Karall; Carsten G. Bönnemann; Johannes Zschocke; Christine Fauth

We report on an autosomal-recessive variant of Ehlers-Danlos syndrome (EDS) characterized by severe muscle hypotonia at birth, progressive scoliosis, joint hypermobility, hyperelastic skin, myopathy, sensorineural hearing impairment, and normal pyridinoline excretion in urine. Clinically, the disorder shares many features with the kyphoscoliotic type of EDS (EDS VIA) and Ullrich congenital muscular dystrophy. Linkage analysis in a large Tyrolean kindred identified a homozygous frameshift mutation in FKBP14 in two affected individuals. Based on the cardinal clinical characteristics of the disorder, four additional individuals originating from different European countries were identified who carried either homozygous or compound heterozygous mutations in FKBP14. FKBP14 belongs to the family of FK506-binding peptidyl-prolyl cis-trans isomerases (PPIases). ER-resident FKBPs have been suggested to act as folding catalysts by accelerating cis-trans isomerization of peptidyl-prolyl bonds and to act occasionally also as chaperones. We demonstrate that FKBP14 is localized in the endoplasmic reticulum (ER) and that deficiency of FKBP14 leads to enlarged ER cisterns in dermal fibroblasts in vivo. Furthermore, indirect immunofluorescence of FKBP14-deficient fibroblasts indicated an altered assembly of the extracellular matrix in vitro. These findings suggest that a disturbance of protein folding in the ER affecting one or more components of the extracellular matrix might cause the generalized connective tissue involvement in this disorder. FKBP14 mutation analysis should be considered in all individuals with apparent kyphoscoliotic type of EDS and normal urinary pyridinoline excretion, in particular in conjunction with sensorineural hearing impairment.


Human Molecular Genetics | 2014

Recessive TTN truncating mutations define novel forms of core myopathy with heart disease

C. Chauveau; Carsten G. Bönnemann; C. Julien; Ay Lin Kho; H. Marks; Beril Talim; P. Maury; M.C. Arne-Bes; Emmanuelle Uro-Coste; Alexander Alexandrovich; Anna Vihola; Sebastian Schafer; B. Kaufmann; L. Medne; Norbert Hubner; A.R. Foley; Mariarita Santi; Bjarne Udd; Haluk Topaloglu; Steven A. Moore; Michael Gotthardt; M.E. Samuels; Mathias Gautel; Ana Ferreiro

Core myopathies (CM), the main non-dystrophic myopathies in childhood, remain genetically unexplained in many cases. Heart disease is not considered part of the typical CM spectrum. No congenital heart defect has been reported, and childhood-onset cardiomyopathy has been documented in only two CM families with homozygous mutations of the TTN gene. TTN encodes titin, a giant protein of striated muscles. Recently, heterozygous TTN truncating mutations have also been reported as a major cause of dominant dilated cardiomyopathy. However, relatively few TTN mutations and phenotypes are known, and titin pathophysiological role in cardiac and skeletal muscle conditions is incompletely understood. We analyzed a series of 23 families with congenital CM and primary heart disease using TTN M-line-targeted sequencing followed in selected patients by whole-exome sequencing and functional studies. We identified seven novel homozygous or compound heterozygous TTN mutations (five in the M-line, five truncating) in 17% patients. Heterozygous parents were healthy. Phenotype analysis identified four novel titinopathies, including cardiac septal defects, left ventricular non-compaction, Emery-Dreifuss muscular dystrophy or arthrogryposis. Additionally, in vitro studies documented the first-reported absence of a functional titin kinase domain in humans, leading to a severe antenatal phenotype. We establish that CM are associated with a large range of heart conditions of which TTN mutations are a major cause, thereby expanding the TTN mutational and phenotypic spectrum. Additionally, our results suggest titin kinase implication in cardiac morphogenesis and demonstrate that heterozygous TTN truncating mutations may not manifest unless associated with a second mutation, reassessing the paradigm of their dominant expression.


Journal of Child Neurology | 2012

Consensus statement on standard of care for congenital myopathies.

Ching H. Wang; James J. Dowling; Kathryn N. North; Mary K. Schroth; Thomas Sejersen; Frederic Shapiro; Jonathan Bellini; Hali E. Weiss; Marc Guillet; Kimberly Amburgey; Susan D. Apkon; Enrico Bertini; Carsten G. Bönnemann; Nigel F. Clarke; Anne M. Connolly; Brigitte Estournet-Mathiaud; Dominic A. Fitzgerald; Julaine Florence; Richard Gee; Juliana Gurgel-Giannetti; Allan M. Glanzman; Brittany Hofmeister; Heinz Jungbluth; Anastassios C. Koumbourlis; Nigel G. Laing; M. Main; Leslie Morrison; Craig Munns; Kristy J. Rose; Pamela M. Schuler

Recent progress in scientific research has facilitated accurate genetic and neuropathological diagnosis of congenital myopathies. However, given their relatively low incidence, congenital myopathies remain unfamiliar to the majority of care providers, and the levels of patient care are extremely variable. This consensus statement aims to provide care guidelines for congenital myopathies. The International Standard of Care Committee for Congenital Myopathies worked through frequent e-mail correspondences, periodic conference calls, 2 rounds of online surveys, and a 3-day workshop to achieve a consensus for diagnostic and clinical care recommendations. The committee includes 59 members from 10 medical disciplines. They are organized into 5 working groups: genetics/diagnosis, neurology, pulmonology, gastroenterology/nutrition/speech/oral care, and orthopedics/rehabilitation. In each care area the authors summarize the committee’s recommendations for symptom assessments and therapeutic interventions. It is the committee’s goal that through these recommendations, patients with congenital myopathies will receive optimal care and improve their disease outcome.


American Journal of Human Genetics | 2012

Cowchock Syndrome Is Associated with a Mutation in Apoptosis-Inducing Factor

Carlo Rinaldi; Christopher Grunseich; Irina F. Sevrioukova; Alice B. Schindler; Iren Horkayne-Szakaly; Costanza Lamperti; Guida Landouré; Marina Kennerson; Barrington G. Burnett; Carsten G. Bönnemann; Leslie G. Biesecker; Daniele Ghezzi; Massimo Zeviani; Kenneth H. Fischbeck

Cowchock syndrome (CMTX4) is a slowly progressive X-linked recessive disorder with axonal neuropathy, deafness, and cognitive impairment. The disease locus was previously mapped to an 11 cM region at chromosome X: q24-q26. Exome sequencing of an affected individual from the originally described family identified a missense change c.1478A>T (p.Glu493Val) in AIFM1, the gene encoding apoptosis-inducing factor (AIF) mitochondrion-associated 1. The change is at a highly conserved residue and cosegregated with the phenotype in the family. AIF is an FAD-dependent NADH oxidase that is imported into mitochondria. With apoptotic insults, a N-terminal transmembrane linker is cleaved off, producing a soluble fragment that is released into the cytosol and then transported into the nucleus, where it triggers caspase-independent apoptosis. Another AIFM1 mutation that predicts p.Arg201del has recently been associated with severe mitochondrial encephalomyopathy in two infants by impairing oxidative phosphorylation. The c.1478A>T (p.Glu493Val) mutation found in the family reported here alters the redox properties of the AIF protein and results in increased cell death via apoptosis, without affecting the activity of the respiratory chain complexes. Our findings expand the spectrum of AIF-related disease and provide insight into the effects of AIFM1 mutations.


PLOS ONE | 2013

Comprehensive Mutation Analysis for Congenital Muscular Dystrophy: A Clinical PCR-Based Enrichment and Next-Generation Sequencing Panel

C. Alexander Valencia; Arunkanth Ankala; Devin Rhodenizer; Shruti Bhide; Martin Robert Littlejohn; Lisa Mari Keong; Anne Rutkowski; Susan E Sparks; Carsten G. Bönnemann; Madhuri Hegde

The congenital muscular dystrophies (CMDs) comprise a heterogeneous group of heritable muscle disorders with often difficult to interpret muscle pathology, making them challenging to diagnose. Serial Sanger sequencing of suspected CMD genes, while the current molecular diagnostic method of choice, can be slow and expensive. A comprehensive panel test for simultaneous screening of mutations in all known CMD-associated genes would be a more effective diagnostic strategy. Thus, the CMDs are a model disorder group for development and validation of next-generation sequencing (NGS) strategies for diagnostic and clinical care applications. Using a highly multiplexed PCR-based target enrichment method (RainDance) in conjunction with NGS, we performed mutation detection in all CMD genes of 26 samples and compared the results with Sanger sequencing. The RainDance NGS panel showed great consistency in coverage depth, on-target efficiency, versatility of mutation detection, and genotype concordance with Sanger sequencing, demonstrating the tests appropriateness for clinical use. Compared to single tests, a higher diagnostic yield was observed by panel implementation. The panels limitation is the amplification failure of select gene-specific exons which require Sanger sequencing for test completion. Successful validation and application of the CMD NGS panel to improve the diagnostic yield in a clinical laboratory was shown.

Collaboration


Dive into the Carsten G. Bönnemann's collaboration.

Top Co-Authors

Avatar

Sandra Donkervoort

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

J. Dastgir

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Ying Hu

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Jain

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Leach

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Waite

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Louis M. Kunkel

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

James J. Collins

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Francesco Muntoni

Great Ormond Street Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge